Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon,...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

401 East Jackson Street, Suite 3300, Tampa, United States

Nick1971 Jun. 17 at 1:20 PM

$AKTX nice we got options trading for this stock finally. Can’t wait to play again. We longs know how this stock works

0 · Reply

SuperGreenToday Jun. 17 at 11:15 AM

$AKTX Share Price: $12.99 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $2.83 – $3.50 Target Zone: $5.08 – $6.21 Potential Upside: 70% ROI Time to Expiration: 120 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LINKBTCFOREVER Jun. 15 at 12:00 PM

$AKTX $AKT.X $AKTX $AKT.X $NVDA $BTC.X LETS GO!!🚀🚀

0 · Reply

BioResearcher Jun. 12 at 7:51 PM

$AKTX It seems they will approve major dilution in coming Meeting ???

1 · Reply

BioResearcher Jun. 9 at 1:54 PM

$AKTX Impressive data compared with an approved multi-billion dollars drug: Trodelvy:

0 · Reply

stckmuncher Jun. 9 at 12:07 AM

$AKTX $ATHE LFG

0 · Reply

HellenicRenegade Jun. 8 at 5:51 PM

$AKTX Just recieved this today, did anyone else get one?

1 · Reply

BioResearcher Jun. 8 at 1:55 PM

$AKTX Impressive data compared with Trodelvy:

0 · Reply

BioResearcher Jun. 5 at 5:57 PM

$AKTX This is one of the data set that make me excited about their drug:

0 · Reply

BioResearcher Jun. 5 at 3:15 PM

$AKTX If they announce a partner, we should see $ 60 - $ 80 here.

1 · Reply

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

Jun 4, 2026, 8:00 AM EDT - 15 days ago

Akari Therapeutics, Proxy statement: Proxy filing

2026-05-28T17:06:49.000Z - 22 days ago

Akari Therapeutics trading resumes

2026-05-28T13:56:00.000Z - 22 days ago

Akari Therapeutics trading halted, volatility trading pause

May 28, 2026, 9:17 AM EDT - 22 days ago

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

2026-05-26T16:51:25.000Z - 24 days ago

Akari Therapeutics trading halted, volatility trading pause

2026-05-26T16:45:36.000Z - 24 days ago

Akari Therapeutics trading resumes

2026-05-26T14:40:48.000Z - 24 days ago

3 Penny Stocks to Watch Now, 5/26/26

LFS QTEX

2026-05-22T19:38:16.000Z - 4 weeks ago

Akari Therapeutics Stock (AKTX) Explodes 242% on Strong Cancer Drug Data and $5.5M Funding Boost

2026-05-22T17:50:10.000Z - 4 weeks ago

Akari Therapeutics trading resumes

2026-05-22T17:45:57.000Z - 4 weeks ago

Akari Therapeutics trading halted, volatility trading pause

May 22, 2026, 8:00 AM EDT - 4 weeks ago

Akari Therapeutics, Proxy statement: Proxy filing

May 21, 2026, 5:01 PM EDT - 4 weeks ago

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

May 21, 2026, 8:30 AM EDT - 4 weeks ago

Akari Therapeutics Announces $5.5 Million Private Placement Offering

May 19, 2026, 7:00 AM EDT - 4 weeks ago

Akari Therapeutics, Quarterly report: Q1 2026

May 18, 2026, 9:05 AM EDT - 4 weeks ago

Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase

2026-05-12T13:57:28.000Z - 5 weeks ago

Akari Therapeutics secures European patent for Thailanstatin-based payloads

May 12, 2026, 8:33 AM EDT - 5 weeks ago

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

May 8, 2026, 8:00 AM EDT - 6 weeks ago

Akari Therapeutics, Registration statement: Registration filing

2026-04-27T13:27:26.000Z - 7 weeks ago

Akari Therapeutics receives Australian patent for core payload technology

Apr 27, 2026, 8:35 AM EDT - 7 weeks ago

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Apr 21, 2026, 9:00 AM EDT - 2 months ago

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

2026-04-20T14:32:23.000Z - 2 months ago

Akari Therapeutics announces presentation of preclinical data for AKTX-101

Apr 20, 2026, 8:35 AM EDT - 2 months ago

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

2026-04-09T13:05:47.000Z - 2 months ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

Apr 9, 2026, 8:50 AM EDT - 2 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

2026-04-08T12:08:04.000Z - 2 months ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

2026-04-06T13:20:35.000Z - 2 months ago

Akari Therapeutics announces strategic partnership with WuXi XDC

Apr 6, 2026, 8:45 AM EDT - 2 months ago

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

2026-04-01T10:13:11.000Z - 2 months ago

Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

2026-03-30T23:51:11.000Z - 2 months ago

Akari Therapeutics trading halted, news pending

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Akari Therapeutics, Annual report: Q4 2025

Mar 18, 2026, 8:05 AM EDT - 3 months ago

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Akari Therapeutics Announces ADS Ratio Change

Mar 13, 2026, 9:15 AM EDT - 3 months ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

2026-02-26T14:24:15.000Z - 4 months ago

Akari Therapeutics appoints Gokhale to its Scientific Advisory Board

Feb 26, 2026, 9:10 AM EST - 4 months ago

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Feb 18, 2026, 9:05 AM EST - 4 months ago

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Feb 12, 2026, 7:00 AM EST - 4 months ago

Akari Therapeutics, Slides: Corporate presentation

Feb 11, 2026, 8:45 AM EST - 4 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Feb 10, 2026, 7:00 PM EST - 4 months ago

Akari Therapeutics, Transcript: Study update

Feb 10, 2026, 7:00 PM EST - 4 months ago

Akari Therapeutics, Press release: Study update

Feb 5, 2026, 9:15 AM EST - 4 months ago

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 2, 2026, 7:00 AM EST - 4 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Jan 26, 2026, 8:45 AM EST - 5 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 23, 2026, 7:00 AM EST - 5 months ago

Akari Therapeutics, Registration statement: Registration Filing

Jan 22, 2026, 7:00 AM EST - 5 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Jan 9, 2026, 9:00 AM EST - 5 months ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 8, 2026, 9:15 AM EST - 5 months ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

Dec 30, 2025, 9:15 AM EST - 6 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Dec 23, 2025, 8:30 AM EST - 6 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 18, 2025, 8:30 AM EST - 6 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Dec 16, 2025, 9:29 AM EST - 6 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Dec 9, 2025, 8:40 AM EST - 6 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Dec 4, 2025, 9:00 AM EST - 7 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 7 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Nov 18, 2025, 8:35 AM EST - 7 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Nov 17, 2025, 7:00 AM EST - 7 months ago

Akari Therapeutics, Registration statement: Registration Filing

Nov 17, 2025, 7:00 AM EST - 7 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 13, 2025, 12:00 AM EST - 7 months ago

Akari Therapeutics, Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 7, 2025, 7:00 AM EST - 8 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 4, 2025, 9:25 AM EST - 8 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Oct 30, 2025, 8:35 AM EDT - 8 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 22, 2025, 9:05 AM EDT - 8 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 8 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 9 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 5, 2025, 6:45 AM EDT - 10 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 10 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 29, 2025, 8:00 AM EDT - 10 months ago

Akari Therapeutics, Registration statement: Registration Filing

Aug 14, 2025, 9:15 AM EDT - 11 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Akari Therapeutics, Quarterly report: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Akari Therapeutics, Registration statement: Registration Filing

Jul 23, 2025, 8:55 AM EDT - 11 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 11 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 1 year ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 13, 2025, 5:14 PM EDT - 1 year ago

Akari Therapeutics, Slides: Company Presentation

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

May 29, 2025, 2:20 PM EDT - 1 year ago

Akari Therapeutics, Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

May 29, 2025, 9:15 AM EDT - 1 year ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 23, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

May 22, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics, Earnings release: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics, Quarterly report: Q1 2025

May 15, 2025, 8:05 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Registration statement: Registration Filing

May 1, 2025, 8:45 AM EDT - 1 year ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Nick1971 Jun. 17 at 1:20 PM

$AKTX nice we got options trading for this stock finally. Can’t wait to play again. We longs know how this stock works

0 · Reply

SuperGreenToday Jun. 17 at 11:15 AM

0 · Reply

LINKBTCFOREVER Jun. 15 at 12:00 PM

$AKTX $AKT.X $AKTX $AKT.X $NVDA $BTC.X LETS GO!!🚀🚀

0 · Reply

BioResearcher Jun. 12 at 7:51 PM

$AKTX It seems they will approve major dilution in coming Meeting ???

1 · Reply

BioResearcher Jun. 9 at 1:54 PM

$AKTX Impressive data compared with an approved multi-billion dollars drug: Trodelvy:

0 · Reply

stckmuncher Jun. 9 at 12:07 AM

$AKTX $ATHE LFG

0 · Reply

HellenicRenegade Jun. 8 at 5:51 PM

$AKTX Just recieved this today, did anyone else get one?

1 · Reply

BioResearcher Jun. 8 at 1:55 PM

$AKTX Impressive data compared with Trodelvy:

0 · Reply

BioResearcher Jun. 5 at 5:57 PM

$AKTX This is one of the data set that make me excited about their drug:

0 · Reply

BioResearcher Jun. 5 at 3:15 PM

$AKTX If they announce a partner, we should see $ 60 - $ 80 here.

1 · Reply

BioResearcher Jun. 4 at 6:33 PM

$AKTX In addition to the recent ASCO 's acceptance of the KRAS–mutated pancreatic cancers abstract, In April, another prestigious conference AACR has also accepted AKTX-101 abstract in solid tumors of the bladder, lung, and breast: So, both ASCO and AACR have validated AKTX-101 result !

0 · Reply

focafoca99 Jun. 4 at 3:33 PM

$AKTX released a CEO Corner detailing its PH1 spliceosome-modulating ADC platform and plans for a Phase‑1 trial by mid‑2027.

1 · Reply

BioResearcher Jun. 4 at 3:17 PM

$AKTX Being accepted by ASCO means a lot to a drug. Here is what another drug company said after their drug got accepted by ASCO: "The ASCO Annual Meeting is widely regarded as the largest and most prestigious medical oncology conference in the world, attracting tens of thousands of leading oncologists, researchers, and healthcare professionals from across the globe. Abstract acceptance at ASCO is determined through a rigorous, peer-review process and represents recognition of the scientific merit and clinical relevance of the submitted research"

0 · Reply

akaritx Jun. 4 at 1:45 PM

$AKTX Check out the video our CEO just released discussing the evolving ADC landscape following ASCO 2026 and how Akari Therapeutics' differentiated PH1 payload platform is positioned to address key challenges in the field. https://vimeo.com/1198231043/f4792442c9?fl=ip&fe=ec

0 · Reply

akaritx Jun. 4 at 1:44 PM

$AKTX Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026 https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-releases-ceo-corner-reflecting-evolving-adc

0 · Reply

BioResearcher Jun. 4 at 12:09 PM

$AKTX AKTX-101 has shown to be outperforming Daraxonrasib ! Daraxonrasib is a miracle drug for Pancreatic cancer. Akari : "The latest data for AKTX-101 in KRas-G12V PDAC builds on preclinical evidence disclosed earlier in a patent filing. In this new study, AKTX-101 exhibited single digit nanomolar cytotoxic potency in all K-Ras G12V PDAC cell lines tested. Of significance, AKTX-101 also outperformed daraxonrasib in multiple PDAC cell lines." From ASCO related news:

0 · Reply

BioResearcher Jun. 3 at 8:13 PM

$AKTX It is interesting that ASCO Peer-Review committee has validated ATTX-101 study and result, here is the post on ASCO website:

0 · Reply

MTN Jun. 3 at 2:40 PM

$AKTX a partnership of $200M or more gets you a MC of around 2B, minus that, this is just a rinse and repeat rug pull of investors, while management goes to conferences, then decides to shelve patented lab work to pivot again and repeat the process.

0 · Reply

BioResearcher Jun. 3 at 2:16 AM

$AKTX So the Stocktwist folks said this company is a scam but the ASCO guys said the data is good and accepted it after peer reviewed. so whom should we believe here ? (no position here)

0 · Reply

MTN Jun. 1 at 8:31 PM

$AKTX don't know which is worse, this or $SPCE

1 · Reply

daleloyd Jun. 1 at 3:22 PM

$AKTX looks like all major supports are broke. We may be free falling for a bit.

1 · Reply

Kirubin Jun. 1 at 2:39 PM

$AKTX 😁🫡💀

0 · Reply

Market Cap	12.52M
Revenue (ttm)	0.00
Net Income (ttm)	-17.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	67,600
Avg Vol	963,382
Day's Range	N/A - N/A
Shares Out	1.15M
Stochastic %K	6%
Beta	1.33
Analysts	Sell
Price Target	$27.00